Mr. Conroy was appointed President and CEO of Exact Sciences in 2009, and named chairman of the board in 2014. Exact Sciences is focused on the early detection and prevention of the deadliest cancers. The company is establishing a new standard for colon cancer screening with its first product, a noninvasive, stool DNA-based screening test called Cologuard.
Mr. Conroy led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its multi-marker Cologuard test. Mr. Conroy established the partnership with Mayo Clinic that led to Cologuard’s development and subsequent 10,000-patient clinical study. The company became the first to simultaneously receive FDA approval and national Medicare coverage, accelerating access to Cologuard for patients 65 and older. The Mayo Clinic collaboration continues to identify changes in DNA associated with the presence of the deadliest cancers.
Before joining Exact Sciences, Mr. Conroy served as president and CEO of Third Wave Technologies, a molecular diagnostics company, where he led the development and commercialization of innovative DNA and RNA analysis products until the company’s acquisition by Hologic, Inc., in 2008. He also held leadership positions at GE Healthcare, a global leader in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery and biopharmaceutical manufacturing.
A native of Michigan, Mr. Conroy earned his Juris Doctorate from the University of Michigan Law School and a Bachelor of Science degree from Michigan State University.